Brief: Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial

Transcode Therapeutics

18/12/2024 13:35

Dec 18 (Reuters) - Transcode Therapeutics Inc  RNAZ.O :
    * TRANSCODE THERAPEUTICS ANNOUNCES SAFETY REVIEW COMMITTEE
APPROVAL OF OPENING THIRD COHORT AND PRELIMINARY RESULTS FROM
FIRST COHORT IN PHASE 1 TTX-MC138 CLINICAL TRIAL
    * SAFETY REVIEW COMMITTEE APPROVES OPENING OF THIRD COHORT
IN
PHASE 1 TRIAL
    * NO SIGNIFICANT SAFETY OR DOSE LIMITING TOXICITIES REPORTED
    * TTX-MC138 SHOWS 66% INHIBITION OF MIR-10B AT 24 HOURS
AFTER
INFUSION

Source text:  ID:nPn6sLSqWa 
Further company coverage:  RNAZ.O 

 ((Reuters.Briefs@thomsonreuters.com;))